Dehydrouramil hydrate hydrochloride (DHU), a stable analogue of alloxan, inhibited the phosphorylation of an endogenous protein of Mr 53 000 catalysed by a Ca2+-calmodulin-dependent protein kinase in extracts of islets of Langerhans. The concentration of DHU required for 5000 inhibition was 0.09 mm. DHU did not inhibit islet cyclic AMP-dependent protein kinase and caused only slight inhibition ofCa2+-phospholipiddependent protein kinase. Inhibition of Ca2+-calmodulin-dependent protein kinase was neither prevented nor reversed by dithiothreitol. DHU did not affect the ability of calmodulin to activate cyclic AMP phosphodiesterase. In intact islets, pre-exposure to DHU impaired the insulin-secretory response to glucose and blocked the potentiatory effect on insulin secretion of forskolin, an activator of adenylate cyclase, and of tetradecanoylphorbol acetate (TPA), an activator of Ca2+-phospholipid-dependent protein kinase. The increase in islet cyclic AMP elicited by forskolin was not affected by DHU. The data are consistent with the hypothesis that protein phosphorylation catalysed by a Ca2+-calmodulin-dependent protein kinase may play a central role in the regulation of insulin secretion.
INTRODUCTION
Diabetogenic compounds such as alloxan are selectively toxic to the pancreatic f-cell, causing rapid inhibition of insulin secretion and eventually f-cell destruction (reviewed by Cooperstein & Watkins, 1981) . Alloxan itself, however, is very unstable in aqueous solution at pH 7 (half-time approx. 1 min). To investigate the mechanism of action of diabetogenic compounds, we have therefore used dehydrouramil hydrate hydrochloride (DHU) , which is structurally related to alloxan but possesses the important advantage of stability in solution. We have shown that DHU is diabetogenic in vivo (Poje & Rocic, 1980; Dominis et al., 1984) ; in vitro DHU inhibited insulin release stimulated by glucose, mannose or 4-methyl-2-oxopentanoate at concentrations that did not affect islet metabolism (Tait et al., 1983) . Inhibition was manifest after a short exposure (5 min) and persisted throughout subsequent incubation in the absence of DHU. As for alloxan, the presence of hexose during exposure of islets to DHU afforded substantial protection against the inhibitory effect. The mechanism of action of alloxan has not been firmly established. It has been shown that alloxan inhibits a Ca2+-calmodulindependent protein kinase in extracts of rat islets (Colca et al., 1983) . This finding is ofconsiderable interest in view of the growing evidence, reviewed by Harrison et al. (1984) , implicating protein phosphorylation as a major control mechanism in the regulation of insulin release. However, protein kinases in addition to Ca2+-calmodulindependent protein kinase are likely to be involved in the secretory process. Interpretation of the inhibitory effect of alloxan on Ca2+-calmodulin-dependent protein kinase depends on whether or not other islet protein kinases are also sensitive to such drugs; the aim of the present study was to establish this point, which has not previously been investigated. Since we find that DHU shares with alloxan the ability to inhibit phosphorylation catalysed by islet Ca2+-calmodulin-dependent protein kinase, we examined the specificity of this effect by determining whether DHU also inhibited islet cyclic AMP-dependent or Ca2+-phospholipid-dependent protein kinases. These kinases were resistant to inhibition by DHU; therefore, in studies with intact islets we examined whether agents that potentiate insulin release via activation of cyclic AMP-dependent or Ca2+-phospholipid-dependent protein kinase (forskolin and TPA respectively) were able to by-pass the block in glucose-stimulated insulin secretion caused by DHU.
Preparation of islets of Langerhans
Islets were prepared by a collagenase digestion method (Coll-Garcia & Gill, 1969) containing SDS (3.75%, w/v), 20 mM-Tris/HCl, pH 6.6, Bromophenol Blue (0.02%, w/v) and glycerol (5%, w/v), and boiling for 5 min. After cooling, 2.5,ul of 2-mercaptoethanol was added to each tube. Proteins were separated by electrophoresis in 16% polyacrylamide gels as described previously (Harrison et al., 1985) . Phosphoproteins were detected by autoradiography using Kodak X-Omat AR-5 film, and the extent of incorporation of 32P into the band of Mr 53 000 was measured by densitometry.
Ca2+-phospholipid-dependent protein kinase was assayed as described by . (50 nmol). When Ca2+ was omitted, the reaction medium also contained EGTA (50 nmol). The extent of incorporation of 32p from [y-32P]ATP into trichloroacetic acid-precipitable material was measured as previously described .
Cyclic AMP-dependent protein kinase was assayed in islet homogenates as described by Sugden et al. (1 979a) . Homogenates were prepared by sonication of 200-400 islets in 50 mM-sodium phosphate, pH 7.0. The assay mixture (final volume 50 1d) contained: sodium phosphate, pH 7.0 (2.5 ,umol), MgCl2 (0.5 /smol), histone type II-A (0.2 mg), EGTA (5 nmol), dithiothreitol (25 nmol), [y-32P]ATP (25 nmol; 0.4 c.p.m./fmol). Samples were taken at appropriate times to determine the incorporation of 32P from [y-32P]ATP into acid-precipitable material as described previously (Sugden et al., 1979a) .
Insulin release
Batches of five islets were preincubated on ice for 10 min in medium containing albumin (2 g/1) in the absence or presence of 1 mM-DHU. Islets were then incubated for 2 h at 37°C with the further additions stated in the Tables or the text. When islet cyclic AMP content was determined, the medium used was a Hepesbuffered bicarbonate medium (Christie & Ashcroft, 1985) and the preincubation and incubation volumes were 50 and 100 ,1 respectively. released into the medium was measured by radioimmunoassay (Ashcroft & Crossley, 1975 (Harrison & Ashcroft, 1982) . Fig. 1 shows that preincubation of islet homogenate with DHU produced a dose-dependent inhibition of the Ca2+-calmodulindependent phosphorylation of the Mr-53 000 protein. The concentration of DHU required for 5000 inhibition was 0.09 mM.
The inhibitory effect of DHU on phosphorylation catalysed by islet Ca2+-calmodulin-dependent protein kinase was not prevented by the simultaneous presence of the thiol reagent dithiothreitol, nor did the addition of dithiothreitol after exposure of the islet extracts to DHU reverse the inhibition by DHU (Fig. 1) .
To determine the specificity of the inhibitory effect of DHU, the sensitivity to DHU of islet cyclic AMPdependent and Ca2+-phospholipid-dependent protein kinases was examined (Fig. 2) Table 3 , DHU had no effect on phosphodiesterase activation either by islet extracts or by authentic calmodulin.
DISCUSSION
Administration of alloxan to rats leads to f8-cell necrosis and production of diabetes. Studies in vitro have shown that alloxan also has a rapid inhibitory effect on insulin secretion that precedes evidence of morphological change (Tomita et al., 1974; McDaniel et al. 1975; Weaver et al., 1978; Tait et al., 1983) . The mechanisms of these effects have not been elucidated, although several studies have suggested that toxic free-radical production may result from the interaction of alloxan with the ,-cell (Heikkila et al., 1976; Grankvist et al., 1979; Fisher & Hamberger, 1980; Asayama et al., 1984) . It is important to note that the rapid action in vitro on insulin secretion may not necessarily involve the same mechanisms as the chronic f-cell destruction. Indeed, although at high concentrations alloxan elicits impairment of metabolic function (Idahl et al., 1977; Tait et al., 1983) , at concentrations below 1 mm the drug causes rather specific inhibition of secretion (Tait et al., 1983) . Studies in vitro on the uptake of alloxan by isolated islets have indicated that the specificity of the drug for the f-cell may result from the relatively high rate of uptake of alloxan by the ,f-cell (Gorus et al., 1982) and also from the relatively low content of peroxidase in the tissue . A possible intracellular target for the acute effect of alloxan has emerged from the finding that an islet Ca2+-calmodulin-dependent protein kinase is inhibited by the drug (Colca et al., 1983) . This effect was seen in extracts of islets; it was also observed that intact islets exposed to alloxan had a decreased activity of Ca2+-calmodulin-dependent protein kinase activity on subse- Ca2+-calmodulin-dependent protein kinase activity (Norling et al., 1984) . Ca2+-calmodulin-dependent protein kinase in brain extracts was also inhibited by alloxan, but the amount of activity extractable from brain was not diminished by administration of the drug in vivo (Norling et al., 1984) , consistent with previous views on the mechanism of tissue specificity. In aqueous solution alloxan rapidly decomposes to the inactive alloxanic acid. This instability has prompted a search for new diabetogenic compounds related to alloxan but stable in solution. We have synthesized a range of such compounds and have demonstrated the potent diabetogenic activity ofDHU, ofdehydroisouramil hydrate hydrochloride and 5-hydroxypseudouric acid (Dominis et al., 1984) . These compounds are of interest not only as useful tools for exploring the mechanism of action of diabetogenic compounds but also because they are potential metabolites of uric acid. We have suggested (Dominis et al., 1984; Tait et al., 1983 ) that endogenous production of such compounds destructive towards the f-cell could be involved in the pathogenesis of Type 1 diabetes.
Like alloxan, DHU also has rapid acute effects on the fl-cell. Since the present study was directed towards investigating a possible mechanism for inhibition of insulin secretion by DHU, it is important to note that several lines of evidence attest to the fact that such inhibition does not arise through non-specific cell damage caused by the drug. Thus Tait et al. (1983) showed that: (i) marked inhibition of insulin release by DHU occurred without impairment of islet energy metabolism; (ii) the presence of glucose during exposure to DHU afforded protection against the inhibitory effects of DHU; (iii) although exposure of islets to 1 mM-DHU in the absence of glucose caused some inhibition of insulin biosynthesis, the effect was modest compared with that on secretion. The present study shows in addition that DHU has no effect on either basal or stimulated islet contents of cyclic AMP.
Previous studies in vitro with DHU have shown that it rapidly and irreversibly inhibits insulin release stimulated by glucose, mannose or 4-methyl-2-oxopentanoate (Tait et al., 1983) . These stimuli are all initiators of insulin secretion, i.e. they are able to elicit secretion in the absence of other agents. However, certain other agents are potentiators of secretion, i.e. their effect on secretion is negligible when present alone, but they are capable of augmenting the secretory response to glucose or other initiator. Two major classes of potentiators are recognized: those agents that increase fl-cell cyclic AMP, e.g. glucagon, and are presumed to act via cyclic AMP-dependent protein kinase (for review see Malaisse & Malaisse-Lagae, 1984) , and those agents that elicit enhanced turnover of inositol phospholipids, e.g. acetylcholine (for review see Best et al., 1984) . The latter event is believed to lead to two distinct intracellular signals, namely inositol trisphosphate, which may serve to mobilize intracellular Ca2+ (Prentki et al., 1984) , and diacylglycerol, which may activate Ca2+-phospholipiddependent protein kinase (Tanigawa et al., 1982) . We have suggested (Harrison et al., 1984 ) that initiation of secretion, which appears to require primarily an increase in intracellular Ca2+, involves protein phosphorylation catalysed by Ca2+-calmodulin-dependent protein kinase. We have further suggested that thephosphorylation of protein catalysed by cyclic AMP-dependent and Ca2+-phospholipid-dependent protein kinases serves an amplificatory role in the action of the potentiators of secretion. The present study provides further support for these views.
As previously shown for alloxan (Colca et al., 1983) , DHU, at concentrations which markedly and specifically inhibit glucose-stimulated insulin secretion (Tait et al., 1983) , inhibits phosphorylation of an endogenous protein of Mr 53000 catalysed by islet Ca2+-calmodulindependent protein kinase. Moreover, the inhibitory effect of DHU on insulin release is not confined to inhibition of initiation of secretion. We show here that the effects on insulin release of two potentiators are also blocked by DHU. Forskolin acts via activation of adenylate cyclase and has been shown to cause enhanced protein phosphorylation catalysed by cyclic AMP-dependent protein kinase in intact islets of Langerhans (Christie & Ashcroft, 1985) . TPA has been shown to activate f-cell Ca2+-phospholipid-dependent protein kinase , and its potentiatory effect on insulin secretion is accompanied by enhanced phosphorylation catalysed by this kinase (Harrison et al., 1984) . One possible explanation for the effect ofDHU on potentiation of secretion is that DHU may inhibit all three protein kinases. However, our data suggest that this is not so. At concentrations of DHU that markedly inhibit Ca2+-calmodulin-dependent protein phosphorylation, the activity of islet cyclic AMP-dependent and Ca2+-phospholipid-dependent protein kinases was little affected. Since the action of forskolin involves increase in cyclic AMP, it was also possible that DHU may act on forskolin-potentiated secretion by interfering with the ability of forskolin to activate adenylate cyclase. Again; however, this possibility can be discounted, since DHU did not lower islet cyclic AMP concentrations augmented by forskolin.
It is important to note that DHU did not affect the phosphorylation of endogenous substrates observed in the absence of Ca2+ and cyclic AMP. Since the latter has been attributed to casein kinase activity (Sugden et al., 1979a) , this observation further supports the view that DHU is rather specific for Ca2+-calmodulin-dependent protein kinase.
These data are therefore consistent with the hypothesis that Ca2+-calmodulin-dependent protein kinase plays a central role in the insulin-secretory process and that activation of cyclic AMP-dependent or Ca2+-phospholipid-dependent protein kinase leads only to amplification of insulin release when this initiation pathway has been activated.
The Ca2+-calmodulin-dependent protein kinase'that we have studied phosphorylates an endogenous protein of Mr 53000 as shown by SDS/polyacrylamide-gel electrophoresis. Properties of this kinase have previously been documented in detail (Harrison & Ashcroft, 1982) , and the activity has been reported in various insulin-' secretory tissues (Landt et al., 1982; Brocklehurst & Hutton, 1983; Schubart & Fields, 1984) , including human islets of Langerhans (Harrison et al., 1985) . The effect of DHU on the measured activity of this kinase may be on the kinase or op its substrate; this point cannot yet be resolved, since separation of kinase and substrate has not been achieved and other substrates for the kinase are unknown. However, the effect of DHU is unlikely to be on calmodulin, since DHU did not affect the ability of calmodulin to bind and activate ''cyclic AMP phospho- diesterase. Our data also suggest'that the effect of DHU on Ca2+-calmodulin-dependent protein kinase does not arise from reaction with thiol groups, since dithiothreitol neither prevented nor reversed the inhibitory action of DHU. The mode of action remains to be established, but DHU is likely to be a valuable tool for investigating further the role of islet protein kinases in the insulin secretory mechanism. These studies were supported by grants from the British Diabetic Association and the Medical Research Council.
